Exchange & Returns Information
Review Details
(0)
| Generic For | LYNPARZA |
|---|---|
| Active Ingredient | OLAPARIB |
| Strength | 150MG |
| Manufacturer | BDR PHARMA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 56 TABLETS | $ 2.45 | $ 137.00 |
$ 116.45
Apply ZARVY26 (-15%)
You save $ 20.55
|
||
| 2 BOXES - 112 TABLETS | $ 2.49 | $ 278.40 |
$ 236.64
Apply ZARVY26 (-15%)
You save $ 41.76
|
||
| ★ Best Value 3 BOXES - 168 TABLETS | $ 2.57 | $ 431.90 |
$ 367.12
Apply ZARVY26 (-15%)
You save $ 64.79
|
Reference information will be available soon.
Bdparp 150 is an oral anticancer formulation containing olaparib 150 mg, a highly effective poly (ADP-ribose) polymerase (PARP) inhibitor.
Its mechanism relies on synthetic lethality: by blocking PARP-mediated DNA single-strand break repair, it forces reliance on the homologous recombination (HR) pathway. In tumor cells with BRCA1 or BRCA2 mutations, where HR repair is defective, this leads to irreversible DNA damage and selective tumor cell death, while largely sparing normal cells.
Bdparp 150 has become a cornerstone in maintenance therapy for ovarian and breast cancers, significantly prolonging progression-free survival. It is also approved for other BRCA-associated malignancies, including pancreatic and prostate cancers.
The tablet formulation supports convenient twice-daily oral dosing, making it suitable for long-term maintenance therapy in eligible patients.
AntiCancer Drugs > Ovarian Cancer (BRCA-mutated advanced cancer)
Bdparp 150 is indicated as first-line or recurrent maintenance therapy for patients with BRCA-mutated ovarian cancer who have responded to platinum-based chemotherapy. It significantly extends progression-free survival (PFS) and delays recurrence, offering improved outcomes without additional cytotoxic burden.
AntiCancer Drugs > Fallopian Tube & Peritoneal Cancer
Approved for maintenance therapy in advanced fallopian tube and primary peritoneal cancers, due to their shared biology with ovarian cancer. Olaparib provides durable disease stabilization following chemotherapy response.
AntiCancer Drugs > Breast Cancer (gBRCA-mutated, HER2-negative)
Indicated for patients with germline BRCA mutations and HER2-negative metastatic or locally advanced breast cancer. Bdparp 150 serves as a non-chemotherapy option, particularly beneficial after prior chemotherapy, offering targeted maintenance with manageable toxicity.
AntiCancer Drugs > Prostate Cancer (mCRPC with BRCA/HRR mutations)
Effective as monotherapy or in combination (e.g., with abiraterone) for metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 or HRR mutations. Demonstrates efficacy in delaying progression, lowering PSA levels, and reducing metastasis.
AntiCancer Drugs > Pancreatic Cancer (gBRCA-mutated)
Indicated as first-line maintenance therapy after ≥16 weeks of platinum-based chemotherapy in patients with metastatic pancreatic adenocarcinoma carrying BRCA mutations. It extends disease control and helps maintain treatment response.
Olaparib functions as a PARP enzyme inhibitor, blocking the repair of single-strand DNA breaks. In tumors with defective homologous recombination repair (such as those with BRCA1/2 mutations), this results in the accumulation of DNA damage, ultimately causing tumor cell death through synthetic lethality.
It demonstrates selective cytotoxicity, preferentially targeting cancer cells while sparing most normal cells, thereby reducing off-target toxicity compared to traditional chemotherapeutics.
With its oral bioavailability and long half-life, olaparib enables sustained PARP inhibition through convenient twice-daily dosing. Beyond direct DNA repair blockade, it also exhibits immune-enhancing effects and may act as a sensitizer to chemotherapy and radiotherapy, broadening its therapeutic impact in oncology.
Ovarian Cancer (BRCA-mutated, 1st-line maintenance):
300 mg orally BID for up to 2 years or until disease progression/toxicity.
→ Discontinue after 2 years if no evidence of disease remains.
HRD-Positive Ovarian Cancer (with Bevacizumab):
300 mg orally BID + Bevacizumab 15 mg/kg IV q3w for a maximum of 2 years.
Breast Cancer (Adjuvant use):
300 mg orally BID for up to 1 year, may be combined with endocrine therapy if indicated.
Other Uses (mCRPC, pancreatic cancer, recurrent ovarian cancer):
300 mg orally BID until progression or unacceptable toxicity.
Important Notes:
Initiate therapy within 8 weeks of completing platinum chemotherapy.
Swallow tablets whole; do not crush or split.
May be taken with or without food.
Adjust dose or interrupt therapy for anemia, nausea, or fatigue.
Requires validated mutation testing (BRCA or HRR) before initiation.
Store at temperatures below 30°C in a dry place
Keep away from direct sunlight
Retain in original blister packaging
Do not refrigerate
Protect from moisture
Ensure childproof storage
Common adverse events: nausea, fatigue, anemia, vomiting, diarrhea
Laboratory abnormalities: decreased hemoglobin, platelets, neutrophils
Serious risks: myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), pneumonitis
Monitoring: regular CBC checks are essential
Management: dose adjustment may be required for hematologic toxicities or persistent gastrointestinal symptoms
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
